Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center

Dr. Martin on the Patient Population of the CARTITUDE-1 Study in R/R Multiple Myeloma

February 23rd 2022

Thomas G. Martin, MD, discusses the patient population of the phase 2 CARTITUDE-1 study in relapsed/refractory multiple myeloma.

Dr. Martin on the 2-Year Follow-Up Results of the CARTITUDE-1 Study in R/R Multiple Myeloma

December 14th 2021

Thomas G. Martin, MD, discusses the 2-year follow-up data of the phase 1/2 CARTITUDE-1 study in relapsed/refractory multiple myeloma, that were presented during the 2021 ASH Annual Meeting & Exposition.

Dr. Martin on the Utility of CAR T-Cell Therapy in Late Relapsed Multiple Myeloma

November 12th 2021

Thomas G. Martin, MD, discusses the utility of CAR T-cell therapy in late relapsed multiple myeloma.

Dr. Martin on the Utility of Quadruplet-Based Regimens in Relapsed/Refractory Multiple Myeloma

September 10th 2021

Thomas G. Martin, MD, discusses the potential utility of quadruplet-based regimens in relapsed/refractory multiple myeloma.

Dr. Martin on Key Advances in Multiple Myeloma

August 31st 2021

Thomas G. Martin, MD, discusses recent key advances in multiple myeloma.

Dr. Martin on the Safety Profile of Bispecific T-Cell Engagers in Multiple Myeloma

April 5th 2021

Thomas G. Martin, MD, discusses the safety profile of bispecific T-cell engagers in multiple myeloma.

Dr. Martin on Determining Transplant Eligibility in Multiple Myeloma

March 18th 2021

Thomas G. Martin, MD, discusses factors that can inform transplant eligibility in multiple myeloma.

Dr. Martin on the Utility of Aggressive Frontline Treatment in Multiple Myeloma

March 15th 2021

Thomas G. Martin, MD, discusses the utility of aggressive frontline treatment in multiple myeloma.

Dr. Martin on the Need for Head-to-Head Comparisons of BTK Inhibitors in MCL

October 12th 2020

Peter Martin, MD, discusses the need for head-to-head comparison of BTK inhibitors in mantle cell lymphoma.

Dr. Martin on the Safety Profile of Belantamab Mafodotin in R/R Multiple Myeloma

August 12th 2020

Thomas G. Martin, MD, discusses the safety profile of belantamab mafodotin-blmf in relapsed/refractory multiple myeloma.

Future of BCMA-Targeted Therapies in Multiple Myeloma

July 17th 2020

Bispecific Antibodies for Multiple Myeloma

July 17th 2020

Differentiating among CAR T Products for Multiple Myeloma

July 17th 2020

Development of CAR T Cells in Multiple Myeloma

July 17th 2020

Using Antibody-Drug Conjugates in Multiple Myeloma

July 17th 2020

BCMA-Targeted Therapies in Multiple Myeloma

July 17th 2020

BELLINI Trial; Venetoclax-Vd in Multiple Myeloma

July 17th 2020

BOSTON Study; SVd in Relapsed/Refractory Multiple Myeloma

July 17th 2020

Lenalidomide-Refractory Multiple Myeloma

July 17th 2020

Daratumumab With Carfilzomib in Frontline Multiple Myeloma

July 17th 2020